24/7 Wall St. on MSN9h
5 'Strong Buy' High-Yield Dividend Stocks Are Top Wall Street Picks for 2025
Analysts are positive on these five top "strong buy" dividend stocks for this year. They make sense for growth and income ...
Morningstar25d
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
“For more than a decade, Pfizer has been a pioneer in delivering targeted therapies for molecular-driven cancers. With today’s accelerated approval of the BRAFTOVI regimen, patients with ...
Yahoo Finance26d
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
NEW YORK, December 20, 2024--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI ® (encorafenib) in combination with ...
Seeking Alpha25d
Pfizer gets FDA accelerated approval for Braftovi
Pfizer (NYSE:PFE) has received FDA accelerated approval for its drug Braftovi in combination with other therapies as a first-line treatment for metastatic colorectal cancer, or mCRC, with a BRAF ...
Stockhouse26d
U.S. FDA Approves Pfizer's BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and ...
Joplin Globe26d
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI ® (encorafenib) in combination with cetuximab (marketed as ERBITUX ® ) and mFOLFOX6 ...
Is Pfizer Inc. (NYSE:PFE) the Best January Dividend Stock to Buy?
We recently compiled a list of the 10 Best January Dividend Stocks To Buy. In this article, we are going to take a look at ...
PMLiVE23d
Pfizer’s Braftovi regimen receives FDA accelerated approval to treat colorectal cancer
Pfizer’s Braftovi (encorafenib) regimen has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat metastatic colorectal cancer (mCRC). The drug has been authorised ...
MarketBeat on MSN4d
Unstoppable Yields: 3 Blue-Chip Stocks to Maximize Returns
The article " Unstoppable Yields: 3 Blue-Chip Stocks to Maximize Returns " first appeared on MarketBeat.
Business Insider25d
Pfizer announces FDA approval of Braftovi combination
Pfizer (PFE) announced that the Food and Drug Administration has approved Braftovi in combination with cetuximab and mFOLFOX6 for the treatment of patients with metastatic colorectal cancer with a ...
Zacks.com on MSN11d
Pfizer Rises 5.6% in a Month: How Should You Play the Stock?
Pfizer’s PFE stock has risen 5.6% in the past month. This was due to the company’s encouraging guidance for 2025 issued in ...
Yahoo Finance23d
Pfizer’s colorectal cancer combo therapy gains accelerated approval from FDA
Pfizer has gained accelerated approval from the US Food and Drug Administration (FDA) for BRAFTOVI (encorafenib) in conjunction with cetuximab and mFOLFOX6 for treating metastatic colorectal ...